BenevolentAI doses participants in BEN-8744 study
The candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis
Read More
Tag: ben-8744
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
